Hexavest Inc. reduced its stake in shares of Eli Lilly And Co (NYSE:LLY) by 54.8% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 258,260 shares of the company’s stock after selling 313,164 shares during the period. Hexavest Inc.’s holdings in Eli Lilly And Co were worth $33,512,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. FDx Advisors Inc. lifted its stake in shares of Eli Lilly And Co by 48.3% during the fourth quarter. FDx Advisors Inc. now owns 19,504 shares of the company’s stock worth $2,257,000 after buying an additional 6,356 shares during the period. Murphy Pohlad Asset Management LLC acquired a new stake in shares of Eli Lilly And Co during the fourth quarter worth $206,000. State of Alaska Department of Revenue lifted its stake in shares of Eli Lilly And Co by 3.3% during the fourth quarter. State of Alaska Department of Revenue now owns 204,487 shares of the company’s stock worth $23,660,000 after buying an additional 6,474 shares during the period. Waverton Investment Management Ltd lifted its stake in shares of Eli Lilly And Co by 1.9% during the fourth quarter. Waverton Investment Management Ltd now owns 12,724 shares of the company’s stock worth $1,472,000 after buying an additional 238 shares during the period. Finally, Sound View Wealth Advisors LLC acquired a new stake in shares of Eli Lilly And Co during the fourth quarter worth $2,773,000. Institutional investors and hedge funds own 79.58% of the company’s stock.

In other Eli Lilly And Co news, SVP Alfonso G. Zulueta sold 4,000 shares of Eli Lilly And Co stock in a transaction on Thursday, January 31st. The shares were sold at an average price of $120.00, for a total value of $480,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Enrique A. Conterno sold 25,000 shares of Eli Lilly And Co stock in a transaction on Friday, February 15th. The shares were sold at an average price of $121.00, for a total transaction of $3,025,000.00. The disclosure for this sale can be found here. Insiders sold 1,040,990 shares of company stock valued at $129,682,182 in the last ninety days. 0.11% of the stock is owned by corporate insiders.

LLY opened at $127.24 on Wednesday. Eli Lilly And Co has a fifty-two week low of $77.09 and a fifty-two week high of $132.13. The company has a debt-to-equity ratio of 1.07, a current ratio of 1.73 and a quick ratio of 1.38. The firm has a market capitalization of $131.54 billion, a price-to-earnings ratio of 22.93, a PEG ratio of 2.41 and a beta of 0.33.

Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings data on Wednesday, February 6th. The company reported $1.33 earnings per share for the quarter, missing analysts’ consensus estimates of $1.36 by ($0.03). Eli Lilly And Co had a net margin of 13.16% and a return on equity of 44.66%. The firm had revenue of $6.44 billion during the quarter, compared to analysts’ expectations of $6.28 billion. During the same period in the previous year, the firm posted $1.14 EPS. The firm’s quarterly revenue was up 4.5% on a year-over-year basis. As a group, equities analysts anticipate that Eli Lilly And Co will post 5.65 EPS for the current year.

LLY has been the subject of a number of research reports. UBS Group decreased their target price on shares of Eli Lilly And Co from $107.53 to $100.00 and set an “average” rating for the company in a research report on Friday, February 8th. Argus restated a “buy” rating on shares of Eli Lilly And Co in a research report on Thursday, December 27th. Zacks Investment Research upgraded shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $121.00 target price for the company in a research report on Wednesday, December 19th. BMO Capital Markets restated a “buy” rating on shares of Eli Lilly And Co in a research report on Wednesday, December 19th. Finally, Cantor Fitzgerald restated a “buy” rating on shares of Eli Lilly And Co in a research report on Monday, February 4th. Ten investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $115.68.

TRADEMARK VIOLATION WARNING: This piece was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://www.watchlistnews.com/hexavest-inc-lowers-stake-in-eli-lilly-and-co-lly/2952717.html.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Recommended Story: What is net income?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.